Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

Additionally, VAX-24 was well-tolerated and demonstrated a safety and tolerability profile similar to Pfizer’s Prevnar 20 ... over with an average gain of +23.9% per year.

Participants were randomized to receive a single dose of either one of three lots of CAPVAXIVE or PPSV23 (pneumococcal 23-valent polysaccharide ... received a pneumococcal vaccine at least one ...

The decision was influenced by the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

As per the professional category of enrolled medical staff, the probiotic group consisted of 10 resident doctors, 20 attending doctors, 23 associate chief doctors ... only 1 out of 98 in the probiotic ...

Currently available PCVs for the recommended age group include Pfizer’s Prevnar 20 and Merck’s Capvaxive. To get the word out about the expanded guidelines and the risk of pneumococcal disease ...

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...